[ad_1]
TakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses
Potential for overcoming ibrutinib resistance demonstrated with a complete response in a patient who had prior treatment with ibrutinib
TakeAim Leukemia data, top-line data previously released in January, highlight emavusertib’s single-agent activity in heavily pretreated AML and HR-MDS patients
LEXINGTON, Mass., June 4, 2022 /PRNewswire/ — Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the presentation of encouraging clinical data from both the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago and online until June 7, 2022.
“We are excited to share data with the oncology community from our TakeAim Lymphoma and TakeAim Leukemia studies at ASCO, including the first release of clinical data investigating the use of emavusertib in combination with ibrutinib in patients with Non-Hodgkin’s Lymphoma,” said James DentzerPresident and Chief Executive Officer of Curis. “These data demonstrate encouraging signs of anti-cancer activity, including a complete response in a primary CNS lymphoma patient who had prior treatment with ibrutinib. We also presented a poster with data from the TakeAim Leukemia study , previously disclosed in a January 2022 press release, demonstrating emavusertib’s encouraging monotherapy activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).”
“In addition to the data from Curis’s studies, there are presentations at the meeting this year by our collaborators at Washington University and the University of Floridawhich help more fully explore emavusertib’s use in tumor types outside of the company’s current focus in hematologic malignancies,” said Robert MartellMD, Ph.D., Head of Research and Development.
TakeAim Lymphoma:
The TakeAim Lymphoma study is a Phase 1/2 open-label, dose escalation, dose expansion clinical trial investigating emavusertib as monotherapy and in combination with ibrutinib in patients with R/R hematologic malignancies, such as non-Hodgkins’s lymphoma and other B cell malignancies. The poster presentation (#7575) made by Dr. Grzegorz NowakowskiDivision of Hematology, Mayo Clinic-Minnesota, today at ASCO includes clinical data from a May 6, 2022 data cutoff, on 13 patients who received the combination, 9 of whom had post-baseline response assessments and were evaluable for response.
Key findings in patients treated with the combination included:
- The combination appeared to be well tolerated
- No dose-limiting toxicities (DLTs) at 200mg of emavusertib; 2 DLTs observed at 300mg (stomatitis and syncope)
- 8 of 9 evaluable patients experienced reduction in tumor burden, including:
- 2 complete responses (CR) (primary CNS lymphoma and mantle cell lymphoma)
- 2 partial responses (PR) (chronic lymphocytic leukemia and mantle cell lymphoma)
- One of the CRs was in a patient who had received prior treatment with ibrutinib, suggesting that the combination may be able to overcome ibrutinib resistance
Next steps for the TakeAim Lymphoma study include further dose expansion in order to determine the Recommended Phase 2 Dose for the combination.
TakeAim Leukemia:
The TakeAim Leukemia study is a Phase 1/2 dose escalation and dose expansion study examining emavusertib use as both monotherapy and in combination with azacitidine or venetoclax in patients with R/R AML or high risk MDS. The poster presentation (#7016) made by Dr. Guillermo Garcia-ManeroChief of the Section of Myelodysplastic Syndromes within the Department of Leukemia at The University of Texas MD Anderson Cancer Center, today at ASCO, includes clinical data from a December 16, 2021 data cutoff for the 49 patients who had been treated with emavusertib in monotherapy as of that date.
Key safety findings included:
- Emavusertib was well-tolerated across multiple dose levels, including at the Recommended Phase 2 …
Full story available on Benzinga.com
[ad_2]
Source link
